Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2000 1
2007 2
2008 3
2009 5
2010 11
2011 9
2012 6
2013 6
2014 10
2015 12
2016 5
2017 12
2018 14
2019 8
2020 14
2021 20
2022 11
2023 11
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Results by year

Filters applied: . Clear all
Page 1
Evidence for the Prevention of Type 2 Diabetes Mellitus.
Shubrook JH, Chen W, Lim A. Shubrook JH, et al. J Am Osteopath Assoc. 2018 Nov 1;118(11):730-737. doi: 10.7556/jaoa.2018.158. J Am Osteopath Assoc. 2018. PMID: 30398570 Free article. Review.
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.
Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E, Abdelmalek MF, Harrison SA, Loomba R, Mantzoros CS, Bugianesi E, Eckel RH, Kaplan LM, El-Serag HB, Cusi K. Kanwal F, et al. Among authors: shubrook jh. Gastroenterology. 2021 Nov;161(5):1657-1669. doi: 10.1053/j.gastro.2021.07.049. Epub 2021 Sep 20. Gastroenterology. 2021. PMID: 34602251 Free PMC article. Review.
Preparing for the NASH Epidemic: A Call to Action.
Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Kanwal F, et al. Among authors: shubrook jh. Gastroenterology. 2021 Sep;161(3):1030-1042.e8. doi: 10.1053/j.gastro.2021.04.074. Epub 2021 Jul 26. Gastroenterology. 2021. PMID: 34416976 Free article.
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ; SURPASS-4 Investigators. Del Prato S, et al. Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18. Lancet. 2021. PMID: 34672967 Clinical Trial.
Reply.
Kanwal F, Shubrook JH, Cusi K. Kanwal F, et al. Among authors: shubrook jh. Gastroenterology. 2022 Jun;162(7):2132-2134. doi: 10.1053/j.gastro.2022.02.019. Epub 2022 Feb 18. Gastroenterology. 2022. PMID: 35183548 No abstract available.
Pharmacology-Insulin.
Shubrook JH, Pfotenhauer KM. Shubrook JH, et al. Prim Care. 2022 Jun;49(2):301-313. doi: 10.1016/j.pop.2021.11.013. Epub 2022 Apr 27. Prim Care. 2022. PMID: 35595484 Review.
Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.
Arslanian SA, Hannon T, Zeitler P, Chao LC, Boucher-Berry C, Barrientos-Pérez M, Bismuth E, Dib S, Cho JI, Cox D; AWARD-PEDS Investigators. Arslanian SA, et al. N Engl J Med. 2022 Aug 4;387(5):433-443. doi: 10.1056/NEJMoa2204601. Epub 2022 Jun 4. N Engl J Med. 2022. PMID: 35658022 Clinical Trial.
161 results